干扰素α-1b联合恩替卡韦治疗高病毒载量慢性乙型肝炎疗效评价

doi:10.3969/j.issn.1672-5069.2016.01.009

摘要/Abstract

摘要： 目的探讨干扰素α-1b联合恩替卡韦（ETV）治疗高病毒载量慢性乙型肝炎（CHB）患者的临床疗效。方法92例高病毒载量（血清HBV DNA≥1×10⁷ IU/ml）CHB患者被分为观察组48例和对照组44例。对照组采用干扰素α-1b治疗,观察组采用干扰素α-1b联合ETV治疗,疗程48 w。比较两组治疗后第12、24、48 w血清丙氨酸氨基转移酶（ALT）复常率、HBV DNA不可检出率、HBeAg阴转率和HBeAg转换率。采用ELISA法检测血清乙型肝炎病毒标记物;使用自动生化分析仪检测肝功能指标;采用荧光定量PCR法检测HBV DNA。结果在治疗第24 w和48 w时,观察组血清ALT复常率分别为68.8%和91.7%,显著高于对照组的34.1%和63.6% （P<0.01）;在治疗第12 w、24 w和48 w时,观察组血清HBV DNA不可检测率分别为45.8%、72.9%和87.5%,显著高于对照组的11.4%、31.8%和47.7%（P<0.01）;在治疗第48 w时,观察组HBeAg阴转率和HBeAg转换率分别为67.6%和62.2%,显著高于对照组的42.9%和37.1% （P<0.05）。结论干扰素α-1b联合ETV治疗血清高病毒载量的CHB患者疗效优于单用干扰素α-1b。

关键词: 慢性乙型肝炎, 干扰素α, -1b, 恩替卡韦, 高病毒载量, 疗效

Abstract: Objective To investigate the clinical efficacy of interferon alfa-1b combined with entecavir（ETV）in treatment of patients with chronic hepatitis B（CHB） and high serum viral loads. Methods 92 patients with CHB and high serum viral load （HBV DNA≥1×10⁷ IU/ml） were divided into observation group （n=48） and control group（n=44）. Patients in the control group were treated with interferon alfa-1b,and patients in the observation group were treated with interferon alfa-1b combined with ETV. The treatment course in two groups lasted for 48 weeks. The recovery rates of serum alanine aminotransferase（ALT）,rates of serum HBV DNA loss, negative rates of HBeAg and the conversion rates of HBeAg to anti-HBe were compared at 12,24 and 48 weeks. Serum HBV markers and HBV DNA levels were routinely detected. Results The recovery rates of serum ALT at week 24 and 48 in observation group were 68.8% and 91.7%,respectively,significantly higher than those in the control group（34.1% and 63.6%,P<0.01）;The negative rates of serum HBV DNA at week 12,24 and 48 in the observation group were 45.8%,72.9% and 87.5%,respectively,which were significantly higher than those in the control group（11.4%,31.8% and 47.7%,P<0.01）;The negative rate of HBeAg and the conversion rate of serum HBeAg at the end of week 48 in the observation group were 67.6% and 62.2%,significantly higher than those in the control group（42.9% and 37.1%,P<0.05）. Conclusion Efficacy of interferon alfa-1b combined with ETV in treatment of patients with CHB and high serum viral load is superior to IFN alfa-1b monotherapy.

Key words: Chronic hepatitis B, Interferon alfa-1b, Entecavir, Serum viral loads, Therapeutic efficacy

占国清, 李芳, 李儒贵, 刘翔, 谭华炳. 干扰素α-1b联合恩替卡韦治疗高病毒载量慢性乙型肝炎疗效评价[J]. 实用肝脏病杂志, 2016, 19(1): 33-36.

Zhan Guoqing, Li Fang, Li Rugui, Liu xiang, Tan Huabing. Efficacy of interferon alfa-1b combined with entecavir in treatment of patients with chronic hepatitis B and high serum viral load[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 33-36.

参考文献

[1] 张雪华,李仲平. 核苷和核苷酸类药物治疗乙型肝炎肝硬化失代偿期患者的临床效果. 临床肝胆病杂志,2015,31（3）:365-369.
[2] Chen YC,Chu CM,Yeh CT,et al. Natural course following the onset of cirrhosis in patients with chronic hepatitis B:a long- term follow-up study. Hepatol Int,2007,1（1）:267-273．
[3] 樊蓉,侯金林,孙剑. 慢性乙型肝炎的个体化治疗策略. 中华内科杂志,2012,51（10）:746-748.
[4] European Association For The Study Of The Liver. EASL clinical practice guidelines:Management of chronic hepatitis B virus infection. J Hepatol,2012,57（1）:167-185.
[5] 陈成伟,陈从新,陈士俊,等. 核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理. 实用肝脏病杂志,2013,16（1）:1-8.
[6] Dandri M,Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut,2012,61（1）:6-17.
[7] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[8] 中华医学会传染病与寄生虫病学分会、肝病学分会. 病毒性肝炎防治方案. 中华肝脏病杂志,2000,8（6）:324-329.
[9] 李勇. 干扰素α-2b 与恩替卡韦联合治疗慢性乙型肝炎患者疗效观察. 中国实用医药,2011,6（35）:136-138.
[10] 陈辉华.恩替卡韦对慢性乙型肝炎患者疗效及血清中HBVDNA载量的影响研究.现代诊断与治疗,2014,25（24）:5585-5586.
[11] Liaw YF,Kao JH,Piratvisuth T,et al. Asian -Pacific consensus statement on the management of chronic hepatitis B:a 2012 update. Hepatol Int,2012,6（3）:531-561.
[12] Bertoletti A,Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immunecontrol of viral infection. Gut,2012,61（12）:1754-1764.
[13] Kim SS,Cheong JY,Cho SW. Current nucleos（t）ide analogue therapy for chronic hepatitis B. Gut Liver,2011,5（3）:278-287.
[14] 袁建军,朱晓继. 聚乙二醇干扰素α-2a对核苷酸类似物治疗后的慢性乙型肝炎患者疗效分析. 成都医学院学报,2014,9（1）:80-81,100.
[15] McMahon BJ. Selecting appropriate management strategies for chronic hepatitis B:who to treat. Am J Gastroenterol,2006,101（ Suppl 1）:S7-S12.
[16] Enomoto M,Tamori A,Nishiguchi S,et al. Combination therapy with a nucleos（t）ide analogue and interferon for chronic hepatitis B:simultaneous or sequential. J Gastroenterol,2013,48（9）:999-1005.
[17] 李媚,唐保东,杨琛,等. α-干扰素联合恩替卡韦治疗慢性乙型肝炎患者疗效Meta分析.实用肝脏病杂志,2014,17（6）:583-587.
[18] 肖作汉,孟冈,王立志. 聚乙二醇干扰素α-2a联合阿德福韦治疗HBeAg阳性慢性乙型肝炎疗效系统评价. 实用肝脏病杂志,2015,18（1）:24-29.
[19] Shi Y,Wu YH,Shu ZY,et al. Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment:a meta-analysis of randomized controlled trials. Hepatobiliary Pancreat Dis Int,2010,9（5）:462-472.
[20] Yokosuka O,Takaguchi K,Fujioka S,et al. Long-term use of entecavir in nucleoside-native Japanese patients with chronic hepatitis B infection. J Hepatol,2010,52（6）:791-799.